Corbus Pharmaceuticals (NASDAQ:CRBP) Upgraded at StockNews.com

StockNews.com upgraded shares of Corbus Pharmaceuticals (NASDAQ:CRBP) to a sell rating in a report issued on Monday.

Other equities analysts also recently issued research reports about the company. Mizuho reiterated an “outperform” rating and set a $74.00 price target on shares of Corbus Pharmaceuticals in a research note on Friday, September 20th. Piper Sandler assumed coverage on Corbus Pharmaceuticals in a research report on Monday, December 2nd. They issued an “overweight” rating and a $35.00 price target for the company. B. Riley cut their price objective on shares of Corbus Pharmaceuticals from $85.00 to $40.00 and set a “buy” rating on the stock in a report on Friday, September 20th. Wedbush reiterated an “outperform” rating and issued a $51.00 target price on shares of Corbus Pharmaceuticals in a report on Monday, November 4th. Finally, Royal Bank of Canada restated an “outperform” rating and set a $82.00 price target on shares of Corbus Pharmaceuticals in a report on Friday, September 20th. One analyst has rated the stock with a sell rating, eight have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $62.00.

Corbus Pharmaceuticals Trading Up 8.2 %

Corbus Pharmaceuticals stock opened at $12.39 on Monday. The firm has a market capitalization of $150.91 million, a price-to-earnings ratio of -2.64 and a beta of 2.57. The firm’s fifty day moving average price is $14.98 and its two-hundred day moving average price is $32.34. Corbus Pharmaceuticals has a 1-year low of $5.67 and a 1-year high of $61.90.

Institutional Investors Weigh In On Corbus Pharmaceuticals

Several large investors have recently modified their holdings of the stock. Vestcor Inc purchased a new position in shares of Corbus Pharmaceuticals during the 3rd quarter valued at $64,000. Avanza Fonder AB purchased a new position in Corbus Pharmaceuticals in the 4th quarter valued at approximately $84,000. JPMorgan Chase & Co. lifted its position in shares of Corbus Pharmaceuticals by 27.0% during the third quarter. JPMorgan Chase & Co. now owns 5,507 shares of the biopharmaceutical company’s stock worth $114,000 after acquiring an additional 1,172 shares in the last quarter. MetLife Investment Management LLC bought a new position in shares of Corbus Pharmaceuticals in the third quarter worth $123,000. Finally, SG Americas Securities LLC purchased a new position in shares of Corbus Pharmaceuticals in the third quarter valued at $151,000. Hedge funds and other institutional investors own 64.64% of the company’s stock.

About Corbus Pharmaceuticals

Corbus Pharmaceuticals Holdings, Inc, a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity.